Abstract
Introduction:ADAMTS13 metalloprotease regulates the multimeric size of von Willebrand factor (VWF) by cleaving the Tyr1605-Met1606 bond in the VWF A2 domain. A minimal region as a functional substrate for ADAMTS13 consisted of 73 amino acid residues from D1596 to R1668 of VWF, designated VWF73, and deletion of the E1660-R1668 region (the C-terminal α helix of VWF A2 domain) led to the loss of cleavage by ADAMTS-13. This suggested that the C-terminal α helix of VWF A2 domain contributes to ADAMTS13 binding to substrate. We will explore whether murine monoclonal antibody (mAb) against the C-terminal α helix of human VWF A2 domain affects the susceptibility of VWF to proteolysis by ADAMTS13 in vitro.Methods:Balb/c mice were immunized with R1659-R1668 of the VWF polypeptide. Monoclonal antibodies (mAbs) were developed by standard hybridoma technology and identified with ELISA. The epitope of mAbs were mapped using recombinant VWF A2 and a series of its truncated mutants with western blot analysis. The effect of mAbs to VWF on its proteolysis by ADAMTS13 was investigated under static/denaturing condition by 1.3% agarose gel electrophoresis and immunologic analysis. The effect of mAbs to GST-VWF73-His on its proteolysis by recombinant ADAMTS13 was measured by 15% SDS-PAGE under reducing condition and western blot analysis.Results: One mAb, designated SZ-179, was found to have high affinity (50 ng/ml) with both a synthetic peptide encompassing residues 1659-1668 and purified pVWF. SZ-179 has isotype of IgG1. It was shown that SZ-179 reacted specifically with recombinant VWF A2 and GST-VWF73-His, respectively, but not with recombinant VWF A1 nor with recombinant VWF A3. Epitope mapping experiments revealed that SZ-179 bound to the distal portion of the VWF A2 domain (E1660-L1666). SZ-179 inhibited proteolytic cleavage of GST-VWF73-His by recombinant ADAMTS13 in a concentration-dependent manner, with a maximal inhibition at concentrations of 50 ug/ml. SZ-179 also reduced degradation of high molecular-weight (HMW)-VWF-multimers under static/denaturing condition dose-dependently, with a maximal inhibition at concentrations of 1 ug/ml.Conclusion:SZ-179, a novel mAb to the A2 Domain of VWF, inhibits the interactions between VWF and ADAMTS13, and prevents excessive degradation of HMW-VWF multimers. This mAb might be useful for the development of therapeutic options to treat bleeding episodes among hemorrhagic diseases. DisclosuresNo relevant conflicts of interest to declare.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.